HR Execs on the Move

Blueprint Medicines

www.blueprintmedicines.com

 
Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Philina Lee
Chief Commercial Officer Profile
Fouad Namouni
President, Research & Development Profile
Kyler Murray
Director, HR Business Partner - Global R&D Profile
Mikaela Levine
Director Process Chemistry R&D Profile
Jennifer Goddard
Vice President, Employment Law and Litigation Profile

Similar Companies

Halo Health

Halo Health’s mission is to streamline communication, so clinicians can focus on care. The Halo Clinical Collaboration Platform provides role-based collaboration that combines scheduling, teams, and communication on a unified platform; allowing the right information to get to the right person at the right time.

ParkMed Urgent Care Center

ParkMed Urgent Care Center is a Alcoa, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Dynavax Technologies Corporation

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates.

Fitness Connection

This website is for sale! fitnessconnectionusa.com is your first and best source for all of the information you’re looking for. From general topics to more of what you would expect to find here, fitnessconnectionusa.com has it all. We hope you find wha...

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.